CD274 and neoplasm: As shown in Fig. 4A, across the 1,229 lines, 240 (19.5%), 797 (64.8%), and 192 (15.6%) were anti-PD-L1 monotherapy, chemotherapy, and anti-PD-(L)1 + chemotherapy, respectively, with NSCLC being the most frequent tumor type (34.3%); median total follow-up was 11.9 months, with 750 (61.0%) progression events.